Cao Yujuan, Wang Xiaodong
Department of Oncology, Peking University Shougang Hospital, Beijing, China.
J Gastrointest Oncol. 2021 Jun;12(3):1191-1196. doi: 10.21037/jgo-21-230.
To summarize the effects of molecular markers on the treatment decision and prognosis of colorectal cancer.
Colorectal cancer is a highly heterogeneous disease. Even colorectal cancers of the same pathological type and clinical stage may have significant differences in treatment efficacy and prognosis. There are three main molecular mechanisms for the occurrence and development of colorectal cancer: chromosomal instability (CIN) pathway, microsatellite instability (MSI), and CpG island methylate phenotype (CIMP). There are multiple molecular markers distributed on each pathway.
We performed a literature search on the PubMed database for studies published in English (from the date of initiation of the database to the year of 2020) using the following subject terms: "colon cancer", "rectal cancer", "colorectal cancer", "molecular markers", "biomarkers", "treatment strategies", and "prognosis".
The different expression states of molecular markers have a significant impact on the treatment decision and prognosis of colorectal cancer. Main colorectal cancer molecular markers include MSI and some important genes. Individualized treatments for tumors with different molecular phenotypes have improved the treatment effectiveness for colorectal cancer. The rational use of molecular markers is valuable for treatment decision-making and the prognosis of patients with colorectal cancer.
总结分子标志物对结直肠癌治疗决策及预后的影响。
结直肠癌是一种高度异质性疾病。即使是相同病理类型和临床分期的结直肠癌,其治疗疗效和预后也可能存在显著差异。结直肠癌发生发展的主要分子机制有三种:染色体不稳定(CIN)途径、微卫星不稳定(MSI)和CpG岛甲基化表型(CIMP)。每条途径上分布有多个分子标志物。
我们在PubMed数据库中进行文献检索,使用以下主题词查找以英文发表的研究(从数据库建立之日至2020年):“结肠癌”、“直肠癌”、“结直肠癌”、“分子标志物”、“生物标志物”、“治疗策略”和“预后”。
分子标志物的不同表达状态对结直肠癌的治疗决策和预后有显著影响。主要的结直肠癌分子标志物包括MSI和一些重要基因。针对不同分子表型的肿瘤进行个体化治疗提高了结直肠癌的治疗效果。合理使用分子标志物对结直肠癌患者的治疗决策和预后具有重要价值。